Dr. Ricardo Hitt

  • Oncólogo médico colaborador en GenesisCare
  • Spoken languages Español e Inglés

Overview

Los tumores avanzados de cabeza y cuello, tratados en centros de referencia, presentan tasas de curación cercanas al 50%

Con más de 30 años de experiencia, el Dr. Hitt es un reputado oncólogo médico especializado en el cáncer de cabeza y cuello. Creador a nivel mundial de los primeros esquemas de tripletes de quimioterapia en este tipo de tumores, ha desarrollado, además, nuevos fármacos en cáncer de cabeza y cuello. Es revisor experto en artículos de este tipo de cáncer (F-1000, Reino Unido), miembro fundador del Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC) y fundador del Comité de Tumores de Cabeza y Cuello del Hospital 12 de Octubre de Madrid.

Desde su formación en medicina, cuenta con la especialidad de medicina interna y de oncología médica, mostró interés en el cáncer de cabeza y cuello, realizando la tesis doctoral ‘Nuevas terapias y nuevos factores pronósticos en tumores de cabeza y cuello’, calificada con sobresaliente Cum Lauden.

Su trayectoria profesional la ha desarrollado en varios hospitales y centros sanitarios, tanto públicos como privados, ha participado en diversos estudios multicéntricos cooperativos y cuenta con más de 150 publicaciones en revistas internacionales y capítulos de libros, en su mayoría sobre tumores de cabeza y cuello. A esto se añade la labor docente que desarrolla, desde hace más de 20 años, como profesor asociado de oncología en la universidad.

Especialidades

  • Cáncer de cabeza y cuello

  • Cáncer de pulmón

  • Cáncer gastrointestinal

  • Tumores de origen desconocido

  • Sarcomas

Miembro de sociedades científicas

  • Sociedad Española de Oncología Médica (SEOM)

  • Sociedad Europea de Oncología Médica (ESMO)

  • Sociedad Americana de Oncología Médica (ASCO)

  • Sociedad Americana Investigacion del cáncer (AACR)

  • Colegio Europeo de Oncología (ESO)

  • Academia de Ciencias de Nueva York (NYAS)

  • EORTC Cabeza y Cuello

  • EORTC Grupo Sarcomas

  • Grupo Español de Cáncer de Cabeza y Cuello

  • F-1000 (revisor experto en artículos de Cáncer de Cabeza y Cuello. Reino Unido)

  • Primer autor y presentador de cuatro trabajos originales en ASCO (Chicago 2003, Chicago 2007, Orlando 2009, Chicago 2016)

Publicaciones

  • Estudios multicéntricos cooperativos. Algunos ejemplos:

    • International Phase II Zactima vs. Placebo, evaluation efficacy and toxicity of Zactima in patients with unresectable or metastatic medullar thiroides carcinoma.
      Principal Investigator: Ricardo Hitt.
      Sponsor: Astra-Zeneca.
      Fecha: 2009-2011.

    • Phase Ib/II BIBW 2992 vs.placebo or both plus BSC in patients with NSCLC after progression to Erlotinib.
      Principal Investigator: Ricardo Hitt.
      Sponsor: Boheringer.
      Fecha: 2009-2012(2 años).

    • Phase II Clinical Trial of BW 2992 vs. Cetuximab (Erbitux) in patients with recurrent/metastatic Head and Neck Cancer after progression to Cisplatin.
      Principal Investigator: Ricardo Hitt.
      Sponsor: Boehringer.
      Fecha: 2009-2010.

    • Randomized Phase III Trial of MAGE vs. Placebo as adyuvant treatment in patients with resectable NSCLC MAGE-AC positive.
      PI: Ricardo Hitt.
      Sponsor: IMCLOM.
      Fecha: 2009-2012.

    • Randomized trial Phase I/II of Cilengitide for evaluation efficacy and toxicity plus Cisplatin, FU, Cetuximab in patients with metastatic/recurrent head and neck cancer. As front line treatment.
      PI: Ricardo Hitt.
      Sponsor: Merck International.

    • Phase II of Panitumumab plus Paclitaxel in patients with metastatic/recurrent head and neck cancer.
      PI: Ricardo Hitt.
      Sponsor. Amgen International.
      Fecha: 2010-2013.

    • Phase II Trial of Cetuximab plus Radiotherapy for evaluation of Laryngectomy free survival in patients with locally advance laryngeal carcinoma Stage III/IV.
      PI.
      Ricardo Hitt.
      Sponsor: Grupo Cooperativo Español de Tumores de Cabeza y Cuello (TTCC).
      Fecha: 2010-2012.

  • Publicaciones. Algunos ejemplos:

    • A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Semin Oncol; 22 (6 Suppl 15); 50-4, 1995 Dec.

    • Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Mayordomo JI; Rivera F; D’az-Puente MT; Lianes P; Colomer R: Lopez-Brea M; Lopez E; Paz-Ares L: Hitt R; Garc’a-Ribas I. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. J Natl Cancer Inst; 87 (11): 803-8, Jun 7.

    • Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer. Hitt R; Hornedo J; Colomer R; Hidalgo M; Brandariz A; Pe–a M; Vicent JA; Cortés Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Semin Oncol; 24 (1 Suppl 2): S2-58-S2-64, 1997 Feb.

    • Lack of ability of ciprofloxacion-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants. Hidalgo M; Hornedo J; Lumbreras C: Trigo JM; Gomez C; Perea S; Ruiz A; Hitt R; Cortes-Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Antimicrob Agents Chemother; 41(5): 1175-7, 1997 May.

    • Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. Garcia-Carbonero R; Hidalgo M; Paz-Ares L; Calzas J; Gomez H; Guerra JA; Hitt R; Hornedo J; Colomer R; Cortes-Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. J Clin Oncol; 15(10): 3178­ 84, 1997 Oct.

    • Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer. Hitt R; Paz-Ares L; Hidalgo M; Colomer R; Brandariz A; Peña M; Alvarez-Vicent J; Hornedo J; Cortes-Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Semin Oncol; 24(6 Suppl 19): S19-20­ S19-24, 1997 Dec.
      Curriculum vitae Ricardo Hitt MD, PhD

    • Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Hitt R; Castellano D; Hidalgo M; Garc’a-Carbonero R; Peña M; Brandariz A; Millan JM; Alvarez-Vicent J; Cortes-Funes H. Division of Medical Oncology, Radiotherapy, Head and Neck Surgery and Radiology, Hospital Universitario Doce de Octubre, Madrid, Spain. Ann Oncol; 9(12): 1347-9, 1998 Dec.

    • P53 expression in locally advanced pharyngeal squamous cell carcinoma. Lassaletta L; Brandariz JA; Benito A; de la Cruz J; Gomez C; Ballestin C; Hitt R; Colomer R; Alvarez-Vicent J. Department of Otolaryngology, La Paz University Hospital, Madrid, Spain. Arch Otolaryngol Head Neck Surg; 125(12): 1356-9m 1999 Dec.

    • Detection of p53 protein in advanced head and neck cancer. Lassaletta L; Brandariz JA; Benito A; Gomez C; Ballestin C; Hitt R; De La Cruz J; Alvarez-Vicent J. Head and Neck Department, University Hospital 12 de Octubre, Madrid, Spain. Acta Otorrinolaringol Esp;50(8): 613-8, 1999 Nov-Dec.

    • Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz­Puente M; Hitt R; Alonso S; Cortes-Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. J Clin Oncol; 17(2):585-92, 1999 Feb.

    • Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine. Castellano D; Hitt R; Cortes-Funes H; Romero A; Rodriguez-Peralto JL. Hospital Universitario Doce de Octubre, Madrid, Spain. J Clin Oncol; 18(3):695-6, 2000 Feb.

    • Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Hitt R; Paz-Ares L; Brandariz A; Castellano D; Pe–a C; Millan JM; Calvo F; Ortiz de Urbina D; Lopez E; Alvarez-Vicent J; Cortes-Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Ann Oncol; 13(10): 1665-73, 2002 Oct.

    • Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors. Castellano D; Hitt R; Ciruelos E; Cortes-Funes H; Colomer R. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Ann Oncol; 14(5):783-7, 2003 May.
      Curriculum vitae Ricardo Hitt MD, PhD

    • Unusual response to gemcitabine in a case of peritoneal malignant fibrous histiocytoma. Hitt R; Jimeno A; Castellano D; Cortes-Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Anticancer Drugs; 14(8): 663-4, 2003 Sep.

    • Primary aortic sarcoma with widespread vascular embolic metastases. Sanchez Muñoz A, Hitt R, Artiles V, Lopez A, Hernández R, Cortés Funes H, Colomer R. Eur J Intern Med. 2003 Jul; 14(4):258-261.

    • Dose and dose intensity effect of adjuvant anthracycline-bassed chemotherapy in early breast cancer: a retrospective analysis. Amador ML; Jimeno A; Hitt R; Cortés­Funes H; Colomer R. Department of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Am J Clin Oncol; 27(3): 269-73, 2004 Jun.

    • Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Hitt R; Jimeno A; Millan JM; Castellano D; Cortes-Funes H. Department of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Cancer; 101(4): 768-75, 2004 Aug 15.

    • Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. Hitt R; Jimeno A; Rodriguez Pinilla M; Rodriguez Peralto JL; Millan JM; Lopez Martin A; Brandariz A; Pe–a C; Cortés Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Br J Cancer; 91(12): 2005-11, 2004 Dec 13.

    • Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer. Rodr’guez Pinilla M; Rodriguez Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez Verde L; Alameda F; S‡nchez Cespedes M. Molecular Pathology Program at the Spanish National Cancer Centre (CNIO), Madrid. Clin Cancer Res; 10(24) 8486-92, 2004 Dec 15.

    • Phase II trial of vinorelbine tartrate in patients with treatment-naive metastasic melanoma. Jimeno A; Hitt R; Quintela Fandino M; Cortés Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Anticancer Drigs; 16(1): 53-7, 2005 Jan.
      Curriculum vitae of Ricardo Hitt MD, PhD

    • Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez J; Ballestin C; Cortés Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Eur J Cancer; 41(3): 453-50, 2005 Feb.

    • Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with carcinoma of the head and neck. Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés Funes H, Hitt R; Gascon P; Amellal N; Harstrick A; Eckardt A. Vall d’Hebron University Hospital, Oncology Service, P Vall d’Hebron 119-129, Barcelona 08035. J Clin Oncol; 23(24): 5568-77, 2005 Aug 20.

    • A retrospective analysis of the outcome of patients with recurrent and/or metastasic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Leon X; Hitt R; Constenla M; Rocca A; Stupp R; Kovocs AF; Amellal N; Bessa EH; Bourhis J. Hospital Santpau, Barcelona, Spain. Clin Oncol (R Coll Radiol); 17(6):418-24, 2005 Sep.

    • Beta-Catenin, Nf-kappaB and FAS protein expression are independent events in head and neck cancer: study of their association with clinical parameters. Rodriguez Pinilla M; Rodriguez Peralto JL; Hitt R; Sanchez J; Sanchez Verde L; Alameda F; Ballestin C; S‡nchez Cespedes M. Molecular Pathology Program, Spanish National Cancer Centre (CNIO), C/Melchor Fernandez Almagro, 3, 28029 Madrid, Spain. Cancer Lett; 230(1): 141-8, 2005 Dec 8.

    • Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. Hitt R; Lopez Pousa A; Mart’nez Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Mart’ JL; Lobo F; Pastor P; Valenti V; Belen J; Sanchez MA; Chaib C; Pallares C; Anton A; Cervantes A; Paz Ares L; Cortés Funes H. Servicio de oncolog’a medica, Hospital Universitario Doce de Octubre, Madrid, Spain. J Clin Oncol; 23(34): 8636-45, 2005 Dec 1.

    • Weekly docetaxel in patients with recurrent and/or metastasic squamous cell carcinoma of the head and neck. Hitt R; Amador ML; Quintela Fandino M; Jimeno A; del Val O; Hernando S; Cortés Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Cancer; 106(1): 106-11, 2006 Jan 1.
      Curriculum vitae Ricardo Hitt MD, PhD

    • Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastasic squamous cell carcinoma of the head and neck. Bourhis J; Rivera F; Mesia; Awada A; Geoffrois L; Borel C; Humblet Y; Lopez Pousa A, Hitt R; Vega Villegas ME; Duck L; Rosine D; Amellal N; Schueler A; Harstrick A. Institut Gustave Roussy, Radiotherapie, Villejuif, France. J Clin Oncol; 24(18): 2866-72, 2006 Jun 20.

    • Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. Quintela Fandino M; Lopez JM; Hitt R; Gamarra S; Jimeno A; Ayala R; Hornedo J; Guzman C; Gilsanz F; Cortés Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. J Clin Oncol; 24(22): 3611-8, 2006 Aug 1.

    • Cetuximab in squamous cell carcinoma of the head and neck. Hitt R; Maria P; Hidalgo M. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Future Oncol; 2(4): 449-57, 2006 Aug.

    • DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck teated with cisplatin­based induction chemotherapy. Quintela Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortés Funes H; Sanchez Cespedes M. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. J Clin Oncol; 24(26):4333-9, 2006 Sep 10.

    • Induction chemotherapy in head and neck cancer. Hitt R. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Ann Oncol; 17 Suppl 10:x42-4, 2006 Sep.

    • Molecular biology in head and neck cancer. Hitt R; Echarri MJ. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Clin Transl Oncol; 8(11): 776-9, 2006 Nov.

    • Primary pulmonary artery sarcoma: report of three cases and review of the literature. Manso L; çlvarez E; Quintela M; Cortes Funes H; Hitt R. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Clin Lung Cancer; 8(4): 277-81, 2007 Jan.
      Curriculum vitae Ricardo Hitt MD, PhD

    • Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastasic squamous cell carcinoma of the head and neck who failed to respond to platinum- based therapy. Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J. Department of Medical Oncology, University Hospital Antwerpen, Edegem, Belgium. J Clin Oncol; 25(16): 2171-7, 2007 Jun 1.

    • Platinum-based chemotherapy plus cetuximab in head and neck cancer. Vermorken JB; Mesia R; Rivera F; Remenar E; Kawecki A; Rottey S; Erfan J; Zabolotnyy D; Kienzer HR; Cupissol D; Peyrade F; Benasso M; Vynnychenko I; De Raucourt D; Bokemeyer C; Schueler A; Amellal N; Hitt R. Antwerp University Hospital, Department of Medical Oncology, Edegem, Belgium. N Engl J Med; 359 (11): 1116­ 27, 2008 Sep 11.

    • CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early- and late- stage oral squamous cell carcinoma – a pilot study. Fialka F; Gruber RM; Hitt R; Opitz L; Brunner E; Schliephake H; Kramer FJ. Department of Oral and Maxillofacial Surgery, University of Goettingen, Robert-Koch-Strasse 40, D-37099 Goettingen, Germany. Oral Oncol; 44(10): 941-8, 2008 Oct.

    • Coexistence of two rare sarcomas: primary leiomyosarcoma of bone and epithelioid hemangioendothelioma of the liver. Gonzalez-Billalabeitia E; Quintela Fandino M; Alemany I; Lopez Alonso G; Ruiz Ollero A; Mart’nez Tello F; Hitt R. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Sarcoma; 2008: 416085, 2008.

    • Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma. Gonzalez Billalabeitia E; Hitt R; Fern‡ndez J; Conde E; Martinez Tello F; Enriquez de Salamanca R; Cortés Funes H. Hematology and Oncology Department, Hospital General Universitario Morales Meseguer, Murcia, Spain. Clin Transl Oncol; 11(7): 479-83, 2009 Jul.

    • Encyclopedia of Cancer. Manfred Schwab editor. Springer Reference 2nd Edition (2009), pag 898-900; Chapter: Docetaxel pharmacology. Author: Hitt R.
      Curriculum vitae of Ricardo Hitt MD, PhD

    • Phase II study of capecitabine as palliative treatment for patients with recurrent and metastasic squamous head and neck cancer after previous platinum-based treatment. Mart’nez Trufero J; Isla D; Adansa JC; Irigoyen A; Hitt R; Gil Arnaiz I; Lambea J; Lecumberri MJ; Cruz JJ. Medical Oncology Department of University Hospital Miguel Servet Hospital, Paseo de Isabel La Catolica 1-3, 50009 Zaragoza, Spain. Br J Cancer; 102(12): 1687-01, 2010 Jun 8.

    • Quality of life of patients receiving platinum-based chemotherapy plus cetuximab firts line for recurrent and/or metastasic squamous cell carcinoma of the head and neck. Mes’a R; Rivera F; Kawecki A; Rottey S; Hitt R; Kienzer H; Cupissol D; De Racourt D; Benasso M; Koralewski P; Delord JP; Bokemeyer C; Curran D; Gross A; Vermorken JB. Department of Medical Oncology, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain. Ann Oncol; 21 (10): 1967-73, 2010 Oct.

    • Diagnosis of unknown primary cancer based on molecular techniques may influence therapeutic approach and improve survival. Homet B; Hitt R; Ghanem I; Cortés Funes H. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Clin Transl Oncol; 12(8): 574-5, 2010 Aug.

    • Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas. Homet Moreno B; Garralda Cabanas E; Hitt R. Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. Clin Transl Oncol; 12(7): 468-72, 2010 Jul.

    • Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastasic squamous cell carcinoma of the head and neck: EXTREME study. Licitra L, Mesia R, Rivera F, Remen‡r E; Hitt R, Efran J, Rottey S, Kawecki A, Zabolotnyy A, Benasso M, Stšrkel S, Senger S, Stroh C, Vermorken JB. Ann Oncol. 2010 Nov 3.

    • Update on the diagnosis of cancer of unknown primary (CUP) origin. Ariza A, Balaña C, Concha , Hitt R, Homet B, Matilla A, Alba E. Clin Transl Oncol, Jul 2011.

    • Phase II study of the combination of cetuximab and weekly paclitaxel in the first –line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Hitt R, A Irigoyen, H Cortés Funes, et al. Annals of Oncol, Aug 23, 2011.
      Curriculum vitae of Ricardo Hitt MD, PhD

    • Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. J M del Campo, Hitt R, P Sebastian, C Carracedo, D Lokanatha, J Bourhis, S Temam, D Cupissol, D De Raucourt, N Maroudias, C M Nutting, N Compton, D Midwinter, L Downie, N Biswas-Baldwin, I El-Hariry and K J Harrington. British J Cancer (2011) 105, 618-627.

    • Update on the diagnosis of cancer of unknown primary (CUP) origin. Ariza A, Balaña Hitt R, Homet B, Matilla A, Alba E. Clin transl oncol 2011 jul; 13 (7).

    • HEAD AND NECK CANCER. MULTIMODALITY MANAGEMENT. Bernier J ed. Management of unresectable head and neck cancer. Hitt R, et al, chapter 24. Jun 2011. Springer.

    • Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. Urba S, van Herpen CM, Sahoo TP, Shin DM, Licitra L, Mezei K, Reuter C, Hitt R, Russo F, Chang SC, Hossain AM, Frimodt-Moller B, Koustenis A, Hong RL. Cancer, october 1; 118. 2012.

    • Taxane-Cisplatin-Fluorouracil As Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta-Analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group. Pierre Blanchard, Jean Bourhis, Benjamin Lacas, Marshall R. Posner, Jan B. Vermorken, Juan J. Cruz Hernandez, Abderrahmane Bourredjem, Gilles Calais, A driano Paccagnella, Ricardo Hitt and Jean-Pierre Pignon on behalf of the Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group. Journal Clinical Oncology, october 20, 2013.

    • A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. R. Hitt, JJ Grau, A Lopez-Pousa, et al. On Behalf TTCC. Ann Oncology (2014)

    • A randomized, phase 2 study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
      T Y Seiwert, J Fayette, D Cupissol, J M Del Campo, P M Clement, R Hitt, M Degardin, W Zhang, A Blackman, E Ehrnrooth, E E W Cohen. Annals of oncology 06/2014

    • Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions
      R I Haddad M Posner R Hitt E E W Cohen J Schulten J -L Lefebvre J B Vermorken
      Annals of Oncology, Volume 29, Issue 5, 1 May 2018, Pages 1130–1140, https://doi.org/10.1093/annonc/mdy102
      Published: 04 April 2018

Premios y distinciones

  • Fundación para la Formación e Investigación en Oncología (FIFO). 1991 -1995.
  • Beca de la Fundación Valgrande para el estudio del marcador tumoral Ca549 en el cáncer de mama metastásico (1994).
  • Beca de la Fundación Valgrande para el estudio multicéntrico del comportamiento de los marcadores tumorales Ca549 y Ca15.3 en pacientes con cáncer de mama con alto riesgo de recaída.
  • Beca de la Fundación Prof. Álvarez-Vicent para nuevos ensayos de Quimioterapia de Inducción en el manejo de pacientes con Cáncer de Cabeza y Cuello localmente avanzado (2003).
  • Premio de la Sociedad Española de Oncología Médica, Tenerife. Ensayo aleatorio de fase III de Paclitaxel, Cisplatino y 5FU vs. Cisplatino 5FU como quimioterapia de inducción en pacientes con el avance local del cáncer de cabeza y cuello. Presentación oral. (2004).
  • Premio Highlight de la Sociedad Americana de Oncología Médica (ASCO), Chicago, 2005. Ensayo aleatorio de fase III de Paclitaxel, Cisplatino y 5FU vs. Cisplatino 5FU como quimioterapia de inducción en pacientes con cáncer de cabeza y cuello localmente avanzado. Presentación oral. (2005).
  • Beca Fullbright. Investigador visitante del Instituto Nacional del Cáncer, Bethesda, Estados Unidos (2005).
  • Becario visitante del Instituto Nacional del Cáncer de Mutua Madrileña, Bethesda, Estados Unidos (2005).
  • Premio EORTC-NCI para el programa de intercambio con el NCI (2005).
  • Lo mejor de ASCO en Orlando, Boston, Los Ángeles, París, Tokio. Orlando 2009. Ensayo aleatorio de fase II/III de dos regímenes de inducción diferentes más quimiorradioterapia (CRT) vs. CRT en pacientes con cáncer de cabeza y cuello no resecable de avance local. Presentación oral, Orlando 2009, EE.UU.